Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models

Journal:

Science Translational Medicine

Published:

2026-06-03

DOI:

10.1126/scitranslmed.adp2595

Affiliations:

23

Authors:

35

Go to article

Institutions	Authors	Share
Institute for Translational Medicine and Liver Disease (ITM), France	15.533333 15.533333	0.44
Alentis Therapeutics AG, Switzerland	3.000000	0.09
Institut Pluridisciplinaire Hubert Curien (IPHC), France	2.500000	0.07
University Hospitals of Strasbourg (HUS), France	2.066667	0.06
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany	2.000000	0.06
University Hospitals Leuven (UZ Leuven), Belgium	2.000000	0.06
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.333333	0.04
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, United States of America (USA)	1.000000	0.03
Stanford University School of Medicine, United States of America (USA)	1.000000	0.03
University of Tübingen (Uni Tübingen), Germany	1.000000	0.03
Strasbourg University Hospital Institute (IHU Strasbourg), France	0.700000	0.02
Groupe Hospitalier Saint-Vincent (GHSV), France	0.500000	0.01
University Medical Center Freiburg, Germany	0.500000	0.01
Massachusetts General Hospital (MGH), United States of America (USA)	0.333333	0.01
Harvard Medical School (HMS), United States of America (USA)	0.333333	0.01
Broad Institute of MIT and Harvard, United States of America (USA)	0.333333	0.01
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain	0.333333	0.01
Catalan Institution for Research and Advanced Studies (ICREA), Spain	0.333333	0.01
University Institute of France (IUF), France	0.200000	0.01